COMMUNIQUÉ DE PRESSE publié le 14/09/2023 à 14:30, il y a 2 années 10 mois Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
COMMUNIQUÉ DE PRESSE publié le 13/09/2023 à 14:30, il y a 2 années 10 mois Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
COMMUNIQUÉ DE PRESSE publié le 12/09/2023 à 14:30, il y a 2 années 11 mois Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
COMMUNIQUÉ DE PRESSE publié le 11/09/2023 à 14:30, il y a 2 années 11 mois Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
COMMUNIQUÉ DE PRESSE publié le 07/09/2023 à 14:30, il y a 2 années 11 mois Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
COMMUNIQUÉ DE PRESSE publié le 30/08/2023 à 14:30, il y a 2 années 11 mois The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
COMMUNIQUÉ DE PRESSE publié le 28/08/2023 à 14:30, il y a 2 années 11 mois Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
COMMUNIQUÉ DE PRESSE publié le 24/08/2023 à 13:00, il y a 2 années 11 mois Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
COMMUNIQUÉ DE PRESSE publié le 17/08/2023 à 14:30, il y a 2 années 11 mois Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
COMMUNIQUÉ DE PRESSE publié le 16/08/2023 à 14:30, il y a 2 années 11 mois Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Publié le 11/08/2026 à 17:45, il y a 1 jour 6 heures DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Publié le 11/08/2026 à 17:40, il y a 1 jour 6 heures Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Publié le 10/08/2026 à 18:00, il y a 2 jours 6 heures AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Publié le 10/08/2026 à 18:00, il y a 2 jours 6 heures AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Publié le 12/08/2026 à 23:30, il y a 55 minutes CCL Industries Announces Record Results for 2026 Second Quarter
Publié le 12/08/2026 à 23:30, il y a 55 minutes Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle
Publié le 12/08/2026 à 23:20, il y a 1 heure 5 minutes RJK Explorations Ltd. Announces Upsize of Previously Announced Private Placement
Publié le 12/08/2026 à 23:05, il y a 1 heure 20 minutes Vox Royalty Reports Q2 2026 Results And Declares Quarterly Dividend
Publié le 12/08/2026 à 22:01, il y a 2 heures 24 minutes Fermi Names Lee McIntire as Chief Executive Officer
Publié le 12/08/2026 à 21:05, il y a 3 heures 20 minutes Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Publié le 12/08/2026 à 19:57, il y a 4 heures 28 minutes EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Publié le 12/08/2026 à 19:37, il y a 4 heures 48 minutes EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
